Compare Sasol Ltd. American Depositary Shares (SSL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sasol Ltd. American Depositary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Sasol Ltd. American Depositary Shares trades at $15.75 (market cap $9.94B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Sasol Ltd. American Depositary Shares is far larger — about 2× Travere Therapeutics Inc. Common Stock's market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sasol Ltd. American Depositary Shares for 2 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SSL | TVTX | |
|---|---|---|
Market Cap | $9.94B | $4.88B |
Volume | 1,412,509 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $15.63 | $67.52 |
52-Week Low | $5.33 | $26.79 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $13.66B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sasol (SSL) trades at $15.58, up 1.83% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected revenue growth from $249.1B in 2025 to $272.1B in 2026. Recent developments include a sustainable aviation fuel agreement with White Desert and board changes, while the CFO's stock sales warrant monitoring.
SSL presents a compelling value opportunity with attractive valuation multiples (P/E 13.74, EV/EBITDA 5.45) and 73% analyst buy ratings. However, risks include negative cash flow trends and high RSI levels suggesting potential overbought conditions. The stock's upside depends on continued operational improvements and commodity market stability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sasol Ltd. American Depositary Shares
Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
